Would you consider stopping EGFR inhibitor in EGFR mutant NSCLC on a patient who was NED for >5 years?  

Like they say, you don't want to change the team that is winning the game. If the patient is tolerating the EGFR TKI appropriately, I recommend continuing it. Recall that TKIs are not curative therapies in the metastatic setting, even though they can induce long-term disease control. One concern the...

It's a great question! My bias would be to lean toward continuation in the absence of significant impact on QOL. Some literature is available describing the experience of long-term responders, but even then, the definition of long-term responders is up about 2-3 years, so well below the duration of ...